发明名称 |
Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor |
摘要 |
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and irinotecan combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and irinotecan combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva(TM)).
|
申请公布号 |
US2005272737(A1) |
申请公布日期 |
2005.12.08 |
申请号 |
US20050144855 |
申请日期 |
2005.06.03 |
申请人 |
CHEN JIANPING;HIGGINS BRIAN;KOLINSKY KENNETH |
发明人 |
CHEN JIANPING;HIGGINS BRIAN;KOLINSKY KENNETH |
分类号 |
A61K31/4706;A61K31/4745;A61K31/498;A61K31/517;A61K31/519;A61K31/5377;A61K39/395;A61K45/06;(IPC1-7):A61K39/395 |
主分类号 |
A61K31/4706 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|